Epidemiology of Invasive Pneumococcal Disease Among High-Risk Adults Since the Introduction of Pneumococcal Conjugate Vaccine for Children
Author(s) -
Rasdiana Muhammad,
Reena OzaFrank,
Elizabeth R. Zell,
Ruth LinkGelles,
K.M. Venkat Narayan,
William Schaffner,
Ann Thomas,
Catherine Lexau,
Nancy M. Bennett,
Monica M. Farley,
Laura Harrison,
Arthur Reingold,
James L. Hadler,
Bernard Beall,
K P Klugman,
Matthew R. Moore
Publication year - 2012
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cis971
Subject(s) - medicine , incidence (geometry) , pneumococcal conjugate vaccine , pediatrics , epidemiology , population , serotype , streptococcus pneumoniae , immunology , environmental health , physics , biology , bacteria , optics , genetics
Certain chronic diseases increase risk for invasive pneumococcal disease (IPD) and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine (PPV23). Since the pediatric introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, incidence of IPD among adults has declined. The relative magnitude of these indirect effects among persons with and without PPV23 indications is unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom